Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melina Stüssi-Helbling

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Trials|January 5, 2021
Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)Pascal Urwyler, Panteleimon Charitos, Stephan Moser, et al.
Allergy|April 22, 2021
Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19Sarah Adamo, Stéphane Chevrier, Carlo Cervia, et al.
Allergy|April 1, 2022
Autoantibodies in COVID-19 correlate with antiviral humoral responses and distinct immune signaturesPatrick Taeschler, Carlo Cervia, Yves Zurbuchen, et al.
Cell Reports. Medicine|February 1, 2021
A distinct innate immune signature marks progression from mild to severe COVID-19Stéphane Chevrier, Yves Zurbuchen, Carlo Cervia, et al.
Frontiers in Immunology|November 15, 2023
Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trialPascal Urwyler, Marina Leimbacher, Panteleimon Charitos, et al.
The Journal of Allergy and Clinical Immunology|November 22, 2020
Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19Carlo Cervia, Jakob Nilsson, Yves Zurbuchen, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Trials|January 5, 2021
Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)Pascal Urwyler, Panteleimon Charitos, Stephan Moser, et al.
Allergy|April 22, 2021
Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19Sarah Adamo, Stéphane Chevrier, Carlo Cervia, et al.
Allergy|April 1, 2022
Autoantibodies in COVID-19 correlate with antiviral humoral responses and distinct immune signaturesPatrick Taeschler, Carlo Cervia, Yves Zurbuchen, et al.
Cell Reports. Medicine|February 1, 2021
A distinct innate immune signature marks progression from mild to severe COVID-19Stéphane Chevrier, Yves Zurbuchen, Carlo Cervia, et al.
Frontiers in Immunology|November 15, 2023
Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trialPascal Urwyler, Marina Leimbacher, Panteleimon Charitos, et al.
The Journal of Allergy and Clinical Immunology|November 22, 2020
Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19Carlo Cervia, Jakob Nilsson, Yves Zurbuchen, et al.
Pageof 2